Antiviral developments. Three new drugs approved for treatment of HIV infection.
Fiddian
A P
AP
D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D048588:Benzoxazines; D002219:Carbamates; D002648:Child; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000627:therapeutic use; D017277:Drug Approval; D005060:Europe; D005663:Furans; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010078:Oxazines / Q000627:therapeutic use; D012194:RNA-Directed DNA Polymerase / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D014481:United States; D000099227:Abacavir
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D002219:Carbamates; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D005663:Furans; D010078:Oxazines; D012194:RNA-Directed DNA Polymerase; D013449:Sulfonamides; D000099227:Abacavir; C095108:amprenavir; C098320:efavirenz